chr11-68386499-C-T
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM1PM2PM5PP2PP3
The ENST00000294304.12(LRP5):c.1199C>T(p.Ala400Val) variant causes a missense change. The variant allele was found at a frequency of 0.000275 in 1,614,080 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A400E) has been classified as Pathogenic.
Frequency
Consequence
ENST00000294304.12 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LRP5 | NM_002335.4 | c.1199C>T | p.Ala400Val | missense_variant | 6/23 | ENST00000294304.12 | NP_002326.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LRP5 | ENST00000294304.12 | c.1199C>T | p.Ala400Val | missense_variant | 6/23 | 1 | NM_002335.4 | ENSP00000294304 | P1 | |
LRP5 | ENST00000529993.5 | c.1199C>T | p.Ala400Val | missense_variant, NMD_transcript_variant | 6/23 | 1 | ENSP00000436652 |
Frequencies
GnomAD3 genomes AF: 0.000138 AC: 21AN: 152218Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000223 AC: 56AN: 251202Hom.: 0 AF XY: 0.000236 AC XY: 32AN XY: 135842
GnomAD4 exome AF: 0.000289 AC: 423AN: 1461744Hom.: 0 Cov.: 32 AF XY: 0.000272 AC XY: 198AN XY: 727192
GnomAD4 genome AF: 0.000138 AC: 21AN: 152336Hom.: 0 Cov.: 32 AF XY: 0.0000940 AC XY: 7AN XY: 74480
ClinVar
Submissions by phenotype
not provided Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | May 02, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 19, 2023 | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 400 of the LRP5 protein (p.Ala400Val). This variant is present in population databases (rs201320326, gnomAD 0.04%). This missense change has been observed in individual(s) with familial exudative vitreoretinopathy (PMID: 34860240). ClinVar contains an entry for this variant (Variation ID: 520692). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on LRP5 protein function. This variant disrupts the p.Ala400 amino acid residue in LRP5. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 16252235, 25711638; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 12, 2023 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 34860240) - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 23, 2023 | Variant summary: LRP5 c.1199C>T (p.Ala400Val) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00022 in 251202 control chromosomes. The observed variant frequency is approximately 4-fold of the estimated maximal expected allele frequency for a pathogenic variant in LRP5 causing Familial Exudative Vitreoretinopathy phenotype (6.3e-05), suggesting this variant might be benign. However, this finding should be interpreted with caution due to the presence of an LRP5 pseudogene that contains exons 3-9 of the gene, a region that includes this variant. c.1199C>T has been reported in the literature in an individual affected with Familial Exudative Vitreoretinopathy, however, in this study it was also not specified whether they were capable of distinguishing between LRP5 and its pseudogene (Tao_2021). Thus, this report does not provide unequivocal conclusions about association of the variant with Familial Exudative Vitreoretinopathy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 34860240). Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 12, 2015 | - - |
Osteoporosis;C0432252:Osteoporosis with pseudoglioma;C0432273:Worth disease;C1843330:Autosomal dominant osteopetrosis 1;C1851402:Exudative vitreoretinopathy 1;C1866079:Bone mineral density quantitative trait locus 1;C1866176:Exudative vitreoretinopathy 4;C4693479:Polycystic liver disease 4 with or without kidney cysts Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 11, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at